ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company focused on inflammasome inhibition and lipid metabolism modulation for patients with kidney disease and neuroinflammatory conditions. The company entered public markets through a de-SPAC business combination and filed an S-1/A registration statement amendment with the SEC on December 6, 2023, a routine post-combination step used to update or extend resale registration coverage for stockholders. Operating in the healthcare and biotechnology sector, ZyVersa's pipeline is led by IC 100, an anti-ASC inflammasome inhibitor in clinical development. The company remains an active post-merger registrant as of the filing date. For full filing history, data timelines, and in-depth SPAC transaction records on ZVSA, sign up for complete access at SpacDesk.